Evidence map›Paper›PMID 41413336›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Protective role of agomelatine via modulation of TLR4/NF-κB: NLRP3/IL-1β signaling pathways in testosterone-induced benign prostatic hyperplasia in rats.

Asmaa Mohamed Abdel-Aziz, Sara M Ahmed, Walaa Yehia Abdelzaher, Nada Amgad Mohamed, Alyaa E Abdelkader, Rasha Fouad Ahmed, Asmaa Mohamed Mahmoud Ali, Al Shimaa Mahmoud Kotb, Alyaa Abdelfattah Abdelmonaem

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Asmaa Mohamed Abdel-AzizDepartment of Medical Pharmacology, Faculty of Medicine, Minia University, Minya, 61519, Egypt. asmaaabdelaziz303@yahoo.com.ORCID http://orcid.org/0000-0002-6184-2901
Sara M AhmedDepartment of Medical Pharmacology, Faculty of Medicine, Minia University, Minya, 61519, Egypt.
Walaa Yehia AbdelzaherDepartment of Medical Pharmacology, Faculty of Medicine, Minia University, Minya, 61519, Egypt.
Nada Amgad MohamedDepartment of Histology and Cell Biology, Faculty of Medicine, Minia University, Minya, 61519, Egypt.
Alyaa E AbdelkaderDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Minia University, Minya, 61519, Egypt.
Rasha Fouad AhmedDepartment of Biochemistry, Faculty of Medicine, Minia University, Minya, 61519, Egypt.
Asmaa Mohamed Mahmoud AliDepartment of Forensic Medicine & Clinical Toxicology, Faculty of Medicine, Minia University, Minya, 61519, Egypt.
Al Shimaa Mahmoud KotbDepartment of Physiology, Faculty of Medicine, Minia University, Minya, 61519, Egypt.
Alyaa Abdelfattah AbdelmonaemDepartment of Medical Pharmacology, Faculty of Medicine, Minia University, Minya, 61519, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benign prostatic hyperplasia (BPH) is a prevalent urological disorder in aging men, frequently linked to hormonal fluctuations. Agomelatine (AGO), a melatonergic receptor agonist and serotonin 2C antagonist, has demonstrated anti-inflammatory and antioxidant properties. This study aimed to explore the potential of AGO in mitigating BPH induced by testosterone propionate (TP) in rats. Male rats received TP (5 mg/kg/day, subcutaneously) to induce BPH and were pretreated with AGO (80 mg/kg/day) for 28 days. AGO inhibited the rise in prostate index, serum prostate-specific antigen (PSA), and testosterone levels compared to the BPH-only group. Histological analysis revealed that AGO significantly improved the pathological alterations in prostate tissue architecture when compared to BPH-only group. Furthermore, AGO notably reduced oxidative stress induced by TP, evidenced by a decrease in lipid peroxidation and preserved levels of reduced glutathione. This reduction in oxidative stress led to a decrease in pro-inflammatory cytokines in the prostate, such as Toll-like receptor 4 (TLR4) and interleukin-1 beta (IL-1β). Additionally, AGO caused a marked decrease in of NLRP3 inflammasome and vascular endothelial growth factor-A (VEGF-A) protein expressions. When compared to the BPH group, AGO's effects also included a reduction in the immunoexpression of nuclear factor kappa B (NF-κB) and myeloid differentiation primary response 88 (MyD88) proteins. The findings from this study provide new evidence that AGO can alleviate testosterone-induced BPH in rats, likely through the inhibition of the TLR4/NFκB and NLRP3/IL-1β signaling pathways. These results suggest that AGO could be a promising therapeutic option for managing BPH.

Indexed as

AcetamidesAnti-Inflammatory AgentsProstatic HyperplasiaAnimalsInterleukin-1betaMaleNaphthalenesNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinOxidative StressProstateRatsRats, Sprague-DawleySignal TransductionTestosteroneTestosterone PropionateAcetamidesagomelatineAnti-Inflammatory AgentsIL1B protein, ratInterleukin-1betaNaphthalenesNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, ratTestosteroneTestosterone PropionateTlr4 protein, ratToll-Like Receptor 4AgomelatineAnti-inflammatoryAnti-oxidativeBenign prostatic hyperplasiaRats

Identifiers

PMID41413336
PMCPMC13086686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.